everolimus

These findings demonstrate that mTORi with everolimus reverses multiple mechanisms of immune resistance in TP53 -mutant HNSCC by promoting immune cell recruitment, suppressing immunosuppressive pathways, and enhancing anti-tumor T cell activity. Collectively, these results support mTORi as a mechanistically rational strategy for reprogramming immune resistance in TP53 -mutant HNSCC and provide a strong preclinical rationale for combining everolimus with immune therapy in patients who are likely to fail immunotherapy.

The mTOR inhibitor Everolimus effectively suppressed tumour growth in an EF-colonied orthotopic model, highlighting its therapeutic potential for HCC patients with high EF burden. Collectively, this work establishes a causal link between tumour-resident E. faecalis and hepatocarcinogenesis, revealing EF-Obg as a cross-kingdom activator of mTOR and providing a rationale for microbiota-guided personalised therapy in HCC.

Altogether, these findings indicate that J4 modulates oligodendroglial lineage populations, enhances myelination, and improves neural connectivity by regulating neuronal hyperactivity. Our results suggest that J4 is a strong therapeutic candidate for addressing the neuropsychiatric manifestations of TSC.

P1, N=50, Recruiting, University of California, San Francisco | Suspended --> Recruiting

P3, N=88, Completed, Centre Hospitalier Universitaire, Amiens | Unknown status --> Completed

CNI minimization - through basiliximab induction, low-dose tacrolimus with mycophenolate, or everolimus conversion - improves renal outcomes without compromising graft survival, despite trade-offs such as mild acute rejection or higher malignancy rates. Muñoz-Serrano et al retrospectively analyzed 594 liver transplant recipients over three decades to identify risk factors for CKD at one year post-transplant. The authors identified older age, female sex, pre-transplant renal dysfunction, and treatment with cyclosporine A as independent risk factors.

P1/2, N=435, Active, not recruiting, Stemline Therapeutics, Inc. | Recruiting --> Active, not recruiting

This case serves as a paradigm for mechanism-driven precision oncology, illustrating that everolimus monotherapy can achieve durable clinical benefit in NF1-deficient recurrent endometrial cancer, with remission persisting even after treatment discontinuation. These findings highlight the clinical relevance of comprehensive molecular diagnostics and support the integration of personalized treatment strategies into modern gynecologic oncology.

P2, N=50, Not yet recruiting, Jonsson Comprehensive Cancer Center

P2/3, N=60, Not yet recruiting, Boston Children's Hospital | Trial completion date: Apr 2030 --> Sep 2030 | Initiation date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2030 --> Sep 2030

Methods We derived a novel PDX from a patient with hormone receptor negative, HER2-positive IBC refractory to neoadjuvant chemotherapy with Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP)...We performed short-tandem repeat (STR) profiling, plotted tumor growth curves for mice treated with alpelisib/everolimus vs. untreated, and immunohistochemistry (IHC), and performed clinical genomic assays...Conclusion We established a PDX of a HER2-positive IBC tumor with a PIK3CA hotspot mutation (H1047R) refractory to TCHP. Targeting the PI3K/mTOR pathway may be useful to overcome resistance in HER2-positive IBC with a H1047R mutation in PIK3CA.

P2, N=94, Not yet recruiting, Yonsei University